Sodium butyrate, a histone deacetylase inhibitor, regulates lymphangiogenic factors in oral cancer cell line HSC-3

Anticancer Research

Volumn 34, Issue 4, 2014, Pages 1701-1708

  Yamamura, Takashi ^a   Matsumoto, Naoyuki ^a   Matsue, Yasuyoshi ^a   Okudera, Michisato ^a   Nishikawa, Youichi ^a   Abiko, Yoshimitsu ^a   Komiyama, Kazuo ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Lymphangiogenesis; Oral cancer; Sodium butyrate; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 2; BUTYRIC ACID; COMPLEMENTARY DNA; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR B; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; CYCLOOXYGENASE 2; HISTONE DEACETYLASE INHIBITOR; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HSC 3 CELL LINE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LYMPHANGIOGENESIS; MICROARRAY ANALYSIS; MOUTH SQUAMOUS CELL CARCINOMA; MUTATION; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; WESTERN BLOTTING; ANGIOGENESIS; CYTOPLASM; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; LYMPH VESSEL; METABOLISM; MOUTH CANCER; MOUTH TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE;

ANGIOGENESIS; LYMPHANGIOGENESIS; ORAL CANCER; SODIUM BUTYRATE; VASCULAR ENDOTHELIAL GROWTH FACTOR;

BUTYRIC ACID; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYTOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYMPHATIC VESSELS; MOUTH NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84902270165     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Hirota K, Wakisaka N, Sawada-Kitamura S, Kondo S, Endo K, Tsuji A, Murono S, and Yoshizaki T: Lymphangiogenesis in regional lymph nodes predicts nodal recurrence in pathological N0 squamous cell carcinoma of the tongue. Histopathology 61: 1065-1071, 2012.
2. Cao Y and Liu Q: Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv Cancer Res 97: 203-224, 2007.
3. Cao Y and Zhong W: Tumor-derived lymphangiogenic factors and lymphatic metastasis. Biomed Pharmacother 61: 534-539, 2007.
4. Aurello P, Rossi Del Monte S, D'Angelo F, Cicchini C, Ciardi A, Bellagamba R, Ravaioli M and Ramacciato G: Vascular endothelial growth factor C and microvessel density in gastric carcinoma: correlation with clinicopathological factors. Our experience and review of the literature. Oncol Res 17: 405-411, 2009.
5. Bo C, Xiaopeng D, Chuanliang P and Xiaogang Z: Expression of vascular endothelial growth factors C and D correlates with lymphangiogenesis and lymph node metastasis in lung adenocarcinoma. Thorac Cardiovasc Surg 57: 291-294, 2009.
6. Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M, Watanabe Y and Pass HI: VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumors. Br J Cancer 81: 54-61, 1999.
7. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholová I, Kauppinen RA, Achen MG, Stacker SA, Alitalo K and Ylä-Herttuala S: VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 92: 1098-1106, 2003.
8. Gallinari P, Di Marco S, Jones P, Pallaoro M and Steinkühler C: HDACs, histone deacetylation and gene transcription: From molecular biology to cancer therapeutics. Cell Res 17: 195-211, 2007.
9. Rosato RR and Grant S: Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2: 30-37, 2003.
10. Zhang XD, Gillespie SK, Borrow JM and Hersey P: The histone deacetylase inhibitor suberic bishydroxamate: A potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 66: 1537-1545, 2003.
11. Jeng JH, Kuo MY, Lee PH, Wang YJ, Lee MY, Lee JJ, Lin BR, Tai TF and Chang MC: Toxic and metabolic effect of sodium butyrate on SAS tongue cancer cells: role of cell cycle deregulation and redox changes. Toxicology 223: 235-247, 2006.
12. Kuroda J, Urade M, Kishimoto H, Noguchi K, Hashitani S, Sakurai K, Nishimura N and Hashimoto-Tamaoki T: Promotion of cell differentiation, and suppression of cell growth and cyclo-oxygenase-2 expression by differentiation-inducing agents in human oral squamous carcinoma SCC25 cells. Int J Oncol 26: 361-367, 2005.
13. Miki Y, Mukae S, Murakami M, Ishikawa Y, Ishii T, Ohki H, Matsumoto M and Komiyama K: Butyrate inhibits oral cancer cell proliferation and regulates expression of secretory phospholipase A2-X and COX2. Anticancer Res 27: 1493-1502, 2007.
14. Wang A, Zeng R and Huang H: Retinoic acid and sodium butyrate as cell cycle regulators in the treatment of oral squamous carcinoma cells. Oncol Res 17: 175-182, 2008.
15. Newmark HL, Lupton JR, Young CW: Butyrate as a differentiating agent: Pharmacokinetics, analogues and current status. Cancer Lett 78: 1-5, 1994.
16. Sugiura T, Inoue Y, Matsuki R, Ishii K, Takahashi M, Abe M and Shirasuna K: VEGFC and VEGFD expression is correlated with lymphatic vessel density and lymph node metastasis in oral squamous cell carcinoma: Implications for use as a prognostic marker. Int J Oncol 34: 673-680, 2009.
17. Mattila MM, Ruohola JK, Karpanen T, Jackson DG, Alitalo K and Härkönen PL: VEGFC induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer 98: 946-951, 2002.
18. Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Tsukiyama A, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I and Kakudo K: Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod Pathol 16: 309-314, 2003.
19. Fujimoto J, Toyoki H, Sato E, Sakaguchi H and Tamaya T: Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers. Br J Cancer 91: 466-469, 2004.
20. Onogawa S, Kitadai Y, Tanaka S, Kuwai T, Kimura S and Chayama K: Expression of VEGFC and VEGFD at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci 95: 32-39, 2004.
21. Kimura Y, Watanabe M, Ohga T, Saeki H, Kakeji Y, Baba H and Maehara Y: Vascular endothelial growth factor C expression correlates with lymphatic involvement and poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep 10: 1747-1751, 2003.
22. Duff SE, Li C, Jeziorska M, Kumar S, Saunders MP, Sherlock D, O'Dwyer ST and Jayson GC: Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 89: 426-430, 2003.
23. charoenrat P, Rhys-Evans P and Eccles SA: Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 92: 556-568, 2001.
24. Nakashima T, Kondoh S, Kitoh H, Ozawa H, Okita S, Harada T, Shiraishi K, Ryozawa S and Okita K: Vascular endothelial growth factor-C expression in human gallbladder cancer and its relationship to lymph node metastasis. Int J Mol Med 11: 33-39, 2003.
25. Tamura M and Ohta Y: Serum vascular endothelial growth factor-C level in patients with primary non-small cell lung carcinoma: A possible diagnostic tool for lymph node metastasis. Cancer 98: 1217-1222, 2003.
26. Duff SE, Li C, Renehan A, O'Dwyer ST, Kumar S: Immunodetection and molecular forms of plasma vascular endothelial growth factor-C. Int J Oncol 22: 339-343, 2003.
27. Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K and Stacker SA: Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (FLK1) and VEGF receptor 3 (FLT4). Proc Natl Acad Sci USA 95: 548-553, 1998.
28. Folkman J: What is the evidence that tumors are angiogenesis dependent? Natl Cancer Inst 82: 4-6, 1990.
29. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
30. Brawer MK, Deering RE, Brown M, Preston SD and Bigler SA: Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 73: 678-687, 1994.
31. Penfold CN, Partridge M, Rojas R and Langdon JD: The role of angiogenesis in the spread of oral squamous cell carcinoma. Br J Oral Maxillofac Surg 34: 37-41, 1996.
32. Partridge M, Gullick WJ, Langdon JD and Sherriff M: Expression of epidermal growth factor receptor on oral squamous cell carcinoma. Br J Oral Maxillofac Surg 26: 381-389, 1988.
33. Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts JA, Benjamin L, Tan X, Manseau EJ, Dvorak AM and Dvorak HF: Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 196: 1497-1506, 2002.
34. Liersch R, Nay F, Lu L and Detmar M: Induction of lymphatic endothelial cell differentiation in embryoid bodies. Blood 107: 1214-1216, 2006.
35. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF and Detmar M: VEGFA induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201: 1089-1099, 2005.
36. Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y and Thyberg J: Comparative evaluation of FGF2-, VEGFA-, and VEGFC-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res 94: 664-670, 2004.
37. Kubo H, Cao R, Brakenhielm E, Makinen T, Cao Y and Alitalo K: Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci USA 99: 8868-8873, 2002.
38. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ and Kim KW: Regulation and destabilization of HIF1αby ARD1-mediated acetylation. Cell 111: 709-720, 2002.
39. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW and Kim KW: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437-443, 2001.
40. Mie Lee Y, Kim SH, Kim HS, Jin Son M, Nakajima H, Jeong Kwon H and Kim KW: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF1α activity. Biochem Biophys Res Commun 300: 241-246, 2003.
41. Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P and Pili R: The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64: 6626-6634, 2004.
42. Yao H, Wang H, Zhang Z, Jiang BH, Luo J and Shi X: Sulforaphane inhibited expression of hypoxia-inducible factor-1αin human tongue squamous cancer cells and prostate cancer cells. Int J Cancer 123: 1255-1261, 2008.
43. Pugh CW and Ratcliffe PJ: Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 9: 677-684, 2003.
44. Simon MP, Tournaire R and Pouyssegur J: The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIFbinding site located in its first intron and by the central factors GATA-2 and ETS1. J Cell Physiol 217: 809-818, 2008.
45. Luttun A, Brusselmans K, Fukao H, Tjwa M, Ueshima S, Herbert JM, Matsuo O, Collen D, Carmeliet P and Moons L: Loss of placental growth factor protects mice against vascular permeability in pathological conditions. Biochem Biophys Res Commun 295: 428-434, 2002.
46. Su JL, Shih JY, Yen ML, Jeng YM, Chang CC, Hsieh CY, Wei LH, Yang PC and Kuo ML: Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C upregulation: A novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res 64: 554-564, 2004.
47. Timoshenko AV, Chakraborty C, Wagner GF and Lala PK: COX2-mediated stimulation of the lymphangiogenic factor VEGFC in human breast cancer. Brit J Cancer 94: 1154-1163, 2006.
48. Narumiya S, Sugimoto Y and Ushikubi F: Prostanoid receptors: Structures, properties, and functions. Physiol Rev 79: 1193-1226, 1999.
49. Tsai PW, Shiah SG, Lin MT, Wu CW and Kuo ML: Upregulation of vascular endothelial growth factor C in breast cancer cells by heregulin-β 1. A critical role of p38/nuclear factor-κB signaling pathway. J Biol Chem 278: 5750-5759, 2003.